Connie S. Zhang

Connie S. Zhang

Auto-generated profile, based on publicly available information

Connie S. Zhang

Division of Cancer Biology and Genetics, Sinclair Cancer Research Institute, Kingston, Canada

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 April 2025 in Cancer Research
Verified
Journal Article
Closed access
BLBrian J. Laight
Brian J. Laight
DHDanielle Harper
Danielle Harper
NDNatasha Dmytryk
Natasha Dmytryk
CZConnie S. Zhang
Connie S. Zhang
CSChangnian Shi
Changnian Shi
PGPeter Alan Greer
Peter Alan Greer
Homeostatic immunoregulatory mechanisms that prevent adverse effects of immune overaction can serve as barriers to successful anticancer immunity, representing attractive targets to improve cancer immunotherapy. Here, we demonstrated the role of the nonreceptor tyrosine kinase Fes, abundantly expressed in immune cells, as an innate intracellular immune checkpoint. Host Fes deficiency delayed tumor onset in a gene dose-dependent manner and improved tumor control, survival, doxorubicin efficacy, and sensitized tumors to anti–PD-1 therapy in murine triple-negative breast cancer and melanoma models. These effects were associated with a shift to an antitumorigenic immune microenvironment. Fes-deficient macrophages displayed increased Toll-like receptor signaling, proinflammatory cytokine production, and antigen presentation to and activation of T cells, leading to increased cancer cell killing in vitro and tumor control in vivo. This study highlights Fes as an innate immune checkpoint with potential as a therapeutic target and a predictive biomarker to guide immune checkpoint inhibitor treatment. Significance: Fes activity modulates the inflammatory cytokine presentation and T-cell priming capabilities of macrophages, supporting the potential of Fes as a target for developing therapeutic and biomarker strategies to improve cancer immunotherapy.

15 July 2025
Verified
Other
Open access
PDF file
BLBrian J. Laight
Brian J. Laight
DHDanielle Harper
Danielle Harper
NDNatasha Dmytryk
Natasha Dmytryk
CZConnie S. Zhang
Connie S. Zhang
CSChangnian Shi
Changnian Shi
PGPeter Alan Greer
Peter Alan Greer
Immune profiling antibody panels

15 July 2025
Verified
Other
Open access
PDF file
BLBrian J. Laight
Brian J. Laight
DHDanielle Harper
Danielle Harper
NDNatasha Dmytryk
Natasha Dmytryk
CZConnie S. Zhang
Connie S. Zhang
CSChangnian Shi
Changnian Shi
PGPeter Alan Greer
Peter Alan Greer
Fes-deficiency improves T cell priming capabilities of BMDMs at a range of SIINFEKL concentrations in a Signal 2-independent mechanism.

15 July 2025
Verified
Other
Open access
PDF file
BLBrian J. Laight
Brian J. Laight
DHDanielle Harper
Danielle Harper
NDNatasha Dmytryk
Natasha Dmytryk
CZConnie S. Zhang
Connie S. Zhang
CSChangnian Shi
Changnian Shi
PGPeter Alan Greer
Peter Alan Greer
Fes-deficiency increases sensitivity to LPS stimulation.

15 July 2025
Verified
Other
Open access
PDF file
BLBrian J. Laight
Brian J. Laight
DHDanielle Harper
Danielle Harper
NDNatasha Dmytryk
Natasha Dmytryk
CZConnie S. Zhang
Connie S. Zhang
CSChangnian Shi
Changnian Shi
PGPeter Alan Greer
Peter Alan Greer
PD-1 therapy delays tumor growth rates only in Fes-/- mice.

15 July 2025
Verified
Other
Open access
PDF file
BLBrian J. Laight
Brian J. Laight
DHDanielle Harper
Danielle Harper
NDNatasha Dmytryk
Natasha Dmytryk
CZConnie S. Zhang
Connie S. Zhang
CSChangnian Shi
Changnian Shi
PGPeter Alan Greer
Peter Alan Greer
Fes is expressed in bone marrow derived macrophages, B cells, and NK cells, but not T cells.